MXPA02007957A
(es)
*
|
2000-02-17 |
2002-11-29 |
Amgen Inc |
Inhibidores de cinasas.
|
ATE430742T1
(de)
*
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
Pyrimidinamine als angiogenesemodulatoren
|
US7205320B2
(en)
|
2001-01-22 |
2007-04-17 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
US7153871B2
(en)
|
2001-01-22 |
2006-12-26 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
|
JP4510442B2
(ja)
*
|
2001-06-26 |
2010-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
TNF−α発現のN−ヘテロ環インヒビター
|
US6939874B2
(en)
*
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
UY27487A1
(es)
*
|
2001-10-17 |
2003-05-30 |
Boehringer Ingelheim Pharma |
Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación
|
JP2005507420A
(ja)
*
|
2001-11-01 |
2005-03-17 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
グリコーゲン合成酵素キナーゼ3β阻害剤としてのアミノベンズアミド誘導体
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
WO2003074515A1
(en)
*
|
2002-03-01 |
2003-09-12 |
Smithkline Beecham Corporation |
Diamino-pyrimidines and their use as angiogenesis inhibitors
|
CN1688553A
(zh)
*
|
2002-06-17 |
2005-10-26 |
史密丝克莱恩比彻姆公司 |
化学方法
|
MXPA05000825A
(es)
*
|
2002-07-19 |
2005-08-29 |
Memory Pharm Corp |
Compuestos de 6-amino-1h-indazol y 4-aminobenzofurano como inhibidores de fosfodiesterasa 4.
|
WO2004009552A1
(en)
|
2002-07-19 |
2004-01-29 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
|
ES2337782T3
(es)
|
2002-07-29 |
2010-04-29 |
Rigel Pharmaceuticals, Inc. |
Metodos para tratar o prevenir enfermedades autoinmunitarias con compuestos de 2,4-pirimidindiamina.
|
WO2004032882A2
(en)
*
|
2002-10-10 |
2004-04-22 |
Smithkline Beecham Corporation |
Chemical compounds
|
DE60334243D1
(de)
|
2002-11-19 |
2010-10-28 |
Memory Pharmaceutical Corp |
Pyridin-n-oxidverbindungen alsphosphodiesterase-4-inhibitoren
|
ES2338545T3
(es)
|
2002-12-20 |
2010-05-10 |
Pfizer Products Inc. |
Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
|
UA80767C2
(en)
*
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
US20040167132A1
(en)
*
|
2003-01-16 |
2004-08-26 |
Geetha Shankar |
Methods of treating conditions associted with an Edg-2 receptor
|
JP4634367B2
(ja)
|
2003-02-20 |
2011-02-16 |
スミスクライン ビーチャム コーポレーション |
ピリミジン化合物
|
TWI395756B
(zh)
|
2003-07-18 |
2013-05-11 |
Amgen Inc |
對肝細胞生長因子具專一性之結合劑
|
ES2421139T3
(es)
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
JP4741491B2
(ja)
|
2003-08-07 |
2011-08-03 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
抗増殖剤としての2,4−ピリミジンジアミン化合物および使用
|
CA2544591A1
(en)
*
|
2003-11-06 |
2005-05-26 |
Celgene Corporation |
Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
|
JP2007532658A
(ja)
*
|
2004-04-16 |
2007-11-15 |
スミスクライン ビーチャム コーポレーション |
がんの治療方法
|
MXPA06011658A
(es)
|
2004-05-14 |
2006-12-14 |
Pfizer Prod Inc |
Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
|
WO2005111016A1
(en)
|
2004-05-14 |
2005-11-24 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
BRPI0510980A
(pt)
|
2004-05-14 |
2007-11-27 |
Pfizer Prod Inc |
derivados de pirimidina para o tratamento do crescimento anormal de células
|
EP1763514A2
(en)
|
2004-05-18 |
2007-03-21 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl substituted pyrimidinediamine compounds and their uses
|
WO2006020564A1
(en)
*
|
2004-08-09 |
2006-02-23 |
Smithkline Beecham Corporation |
Pyrimidin derivatives for the treatment of multiple myeloma
|
BRPI0516597A
(pt)
*
|
2004-10-13 |
2008-09-16 |
Wyeth Corp |
composto da fórmula
|
GB2420559B
(en)
*
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
CN100516049C
(zh)
|
2004-11-16 |
2009-07-22 |
永信药品工业股份有限公司 |
抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
|
JP5095409B2
(ja)
|
2004-11-24 |
2012-12-12 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
スピロ2,4−ピリミジンジアミン化合物およびその使用
|
AU2005312048B2
(en)
|
2004-11-30 |
2012-08-02 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
MX2007007189A
(es)
|
2005-01-19 |
2010-09-28 |
Rigel Pharmaceuticals Inc |
Prodrogas de compuestos de 2,4-pirimidindiamina y sus usos.
|
US8227455B2
(en)
|
2005-04-18 |
2012-07-24 |
Rigel Pharmaceuticals, Inc. |
Methods of treating cell proliferative disorders
|
WO2006129100A1
(en)
*
|
2005-06-03 |
2006-12-07 |
Glaxo Group Limited |
Novel compounds
|
KR101312225B1
(ko)
|
2005-06-08 |
2013-09-26 |
리겔 파마슈티칼스, 인크. |
Jak 경로의 억제를 위한 조성물 및 방법
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US8926945B2
(en)
|
2005-10-07 |
2015-01-06 |
Guerbet |
Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
|
US8986650B2
(en)
|
2005-10-07 |
2015-03-24 |
Guerbet |
Complex folate-NOTA-Ga68
|
BRPI0619057A2
(pt)
*
|
2005-11-29 |
2011-09-20 |
Smithkline Beecham Corp |
formulação farmacêutica de uso tópico, uso de um ou mais compostos, e, compostos
|
SI1954281T1
(sl)
|
2005-11-29 |
2011-06-30 |
Glaxosmithkline Llc |
Postopek zdravljenja raka
|
US20080108664A1
(en)
|
2005-12-23 |
2008-05-08 |
Liu Belle B |
Solid-state form of AMG 706 and pharmaceutical compositions thereof
|
TW200736232A
(en)
*
|
2006-01-26 |
2007-10-01 |
Astrazeneca Ab |
Pyrimidine derivatives
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
CA2641713C
(en)
|
2006-02-10 |
2011-11-22 |
Amgen Inc. |
Hydrate forms of amg706
|
JP2009528295A
(ja)
|
2006-02-24 |
2009-08-06 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jak経路の阻害のための組成物および方法
|
WO2007143483A2
(en)
*
|
2006-06-01 |
2007-12-13 |
Smithkline Beecham Corporation |
Combination of pazopanib and lapatinib for treating cancer
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
JP5161233B2
(ja)
*
|
2006-10-19 |
2013-03-13 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
自己免疫疾患の処置のためのjakキナーゼの阻害剤としての2,4−ピリミジンアミン誘導体
|
US7687522B2
(en)
|
2006-12-20 |
2010-03-30 |
Amgen Inc. |
Substituted pyridines and pyrimidines and their use in treatment of cancer
|
WO2008086014A2
(en)
|
2007-01-09 |
2008-07-17 |
Amgen Inc. |
Bis-aryl amide derivatives useful for the treatment of cancer
|
FR2911604B1
(fr)
|
2007-01-19 |
2009-04-17 |
Sanofi Aventis Sa |
Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
|
EP2114898A2
(en)
|
2007-02-16 |
2009-11-11 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
|
ES2465673T3
(es)
*
|
2007-04-16 |
2014-06-06 |
Hutchison Medipharma Enterprises Limited |
Derivados de pirimidina
|
RS56743B1
(sr)
|
2007-08-21 |
2018-03-30 |
Amgen Inc |
Humani c-fms antigen vezujući proteini
|
EP2058307A1
(en)
|
2007-11-12 |
2009-05-13 |
Cellzome Ag |
Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
KR20100132550A
(ko)
|
2008-04-16 |
2010-12-17 |
포톨라 파마슈티컬스, 인코포레이티드 |
syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드
|
WO2009131687A2
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
MX353308B
(es)
|
2008-05-21 |
2018-01-08 |
Ariad Pharma Inc |
Derivados fosforosos como inhibidores de cinasa.
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
US20100029689A1
(en)
*
|
2008-07-02 |
2010-02-04 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
US20110301113A1
(en)
*
|
2008-09-26 |
2011-12-08 |
Concert Pharmaceuticals Inc. |
Pyridineamine derivatives
|
FR2942227B1
(fr)
|
2009-02-13 |
2011-04-15 |
Guerbet Sa |
Utilisation de tampons pour la complexation de radionucleides
|
US20120232102A1
(en)
|
2009-09-30 |
2012-09-13 |
Chun-Fang Xu |
Methods Of Administration And Treatment
|
EP2490536A4
(en)
*
|
2009-10-23 |
2013-04-17 |
Glaxo Wellcome Mfg Pte Ltd |
COMPOSITION AND METHOD
|
WO2011058179A1
(en)
|
2009-11-16 |
2011-05-19 |
Ratiopharm Gmbh |
5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
|
WO2011069053A1
(en)
|
2009-12-04 |
2011-06-09 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
|
UY33164A
(es)
*
|
2010-01-06 |
2011-08-31 |
Glaxo Wellcome Mfg Pte Ltd |
Metodo de tratamiento
|
US10166142B2
(en)
|
2010-01-29 |
2019-01-01 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
CA2794153C
(en)
|
2010-03-25 |
2018-01-02 |
Glaxosmithkline Llc |
Substituted indoline derivatives as perk inhibitors
|
CA2798578C
(en)
|
2010-05-21 |
2015-12-29 |
Chemilia Ab |
Novel pyrimidine derivatives
|
JP2013526613A
(ja)
*
|
2010-05-26 |
2013-06-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
組合せ
|
CN103038230B
(zh)
|
2010-06-04 |
2016-05-25 |
霍夫曼-拉罗奇有限公司 |
作为lrrk2调节剂的氨基嘧啶衍生物
|
WO2011161217A2
(en)
|
2010-06-23 |
2011-12-29 |
Palacký University in Olomouc |
Targeting of vegfr2
|
JP5903433B2
(ja)
|
2010-08-26 |
2016-04-13 |
ノバルティス アーゲー |
癌の治療に有用なvegfr阻害剤およびmek阻害剤の医薬的組み合わせ
|
US20130172378A1
(en)
|
2010-09-14 |
2013-07-04 |
Glaxosmithkline Llc |
Combination of BRAF and VEGF Inhibitors
|
MX2013004086A
(es)
*
|
2010-10-14 |
2013-07-05 |
Ariad Pharma Inc |
Metodos para inhibir proliferacion celular en cancers accionados por egfr.
|
EP3176154B1
(en)
|
2010-11-01 |
2019-02-20 |
Portola Pharmaceuticals, Inc. |
Benzamides and nicotinamides as syk modulators
|
US20130317029A1
(en)
|
2010-11-01 |
2013-11-28 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
WO2012061428A2
(en)
|
2010-11-01 |
2012-05-10 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
NO2638031T3
(el)
|
2010-11-10 |
2018-03-10 |
|
|
WO2012068549A2
(en)
|
2010-11-19 |
2012-05-24 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
WO2012073254A1
(en)
|
2010-11-29 |
2012-06-07 |
Hetero Research Foundation |
A process for the preparation of pazopanib using novel intermediate
|
CN102093340B
(zh)
*
|
2010-12-09 |
2013-07-17 |
天津药物研究院 |
2-甲基吲唑衍生物的制备及用途
|
CN102093339B
(zh)
*
|
2010-12-09 |
2013-06-12 |
天津药物研究院 |
一类嘧啶衍生物的制备及用途
|
CN102060848B
(zh)
*
|
2010-12-09 |
2013-09-18 |
天津药物研究院 |
芳香胺取代的嘧啶衍生物的制备及用途
|
WO2012082337A2
(en)
|
2010-12-17 |
2012-06-21 |
Glaxo Wellcome Manufacturing Pte Ltd |
Combination
|
FR2968999B1
(fr)
|
2010-12-20 |
2013-01-04 |
Guerbet Sa |
Nanoemulsion de chelate pour irm
|
EP2672969A4
(en)
|
2011-02-01 |
2014-07-16 |
Glaxosmithkline Intellectual Property Ltd |
ASSOCIATION
|
DK2688887T3
(en)
|
2011-03-23 |
2015-06-29 |
Amgen Inc |
DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3
|
ES2587864T3
(es)
|
2011-03-24 |
2016-10-27 |
Noviga Research Ab |
Derivados de pirimidina
|
US8916557B2
(en)
*
|
2011-04-19 |
2014-12-23 |
Bayer Intellectual Property Gmbh |
Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines
|
CA2832504C
(en)
|
2011-05-04 |
2019-10-01 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
TWI555737B
(zh)
|
2011-05-24 |
2016-11-01 |
拜耳知識產權公司 |
含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
EP2755948B1
(en)
*
|
2011-09-16 |
2016-05-25 |
Bayer Intellectual Property GmbH |
Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
|
FR2980364B1
(fr)
|
2011-09-26 |
2018-08-31 |
Guerbet |
Nanoemulsions et leur utilisation comme agents de contraste
|
BR112014010551A2
(pt)
|
2011-10-31 |
2017-05-02 |
Glaxosmithkline Ip Dev Ltd |
composição adequada para a reconstituição em uma suspensão aquosa, pó para a combinação direta para o uso em composição farmacêutica, formulação farmacêutica de suspensão oral, e, suspensão oral
|
US9359308B2
(en)
|
2011-11-23 |
2016-06-07 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
CN103159742B
(zh)
*
|
2011-12-16 |
2015-08-12 |
北京韩美药品有限公司 |
5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
CN103373989B
(zh)
*
|
2012-04-28 |
2016-04-13 |
上海医药工业研究院 |
盐酸帕唑帕尼的中间体的制备方法
|
JP6469567B2
(ja)
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Egfr発動性がんの細胞増殖阻害用化合物
|
US9505749B2
(en)
|
2012-08-29 |
2016-11-29 |
Amgen Inc. |
Quinazolinone compounds and derivatives thereof
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
WO2014060493A2
(en)
|
2012-10-18 |
2014-04-24 |
Bayer Pharma Aktiengesellschaft |
N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
|
US9670161B2
(en)
|
2012-10-18 |
2017-06-06 |
Bayer Pharma Aktiengesellschaft |
5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
|
TW201418243A
(zh)
|
2012-11-15 |
2014-05-16 |
Bayer Pharma AG |
含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
|
WO2014076091A1
(en)
|
2012-11-15 |
2014-05-22 |
Bayer Pharma Aktiengesellschaft |
5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
|
CN103864764A
(zh)
*
|
2012-12-11 |
2014-06-18 |
齐鲁制药有限公司 |
吲唑取代的嘧啶胺衍生物、其制备方法和用途
|
US9802923B2
(en)
*
|
2012-12-17 |
2017-10-31 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of pazopanib or salts thereof
|
WO2014097152A1
(en)
|
2012-12-17 |
2014-06-26 |
Ranbaxy Laboratories Limited |
Process for the preparation of pazopanib or salts thereof
|
CN103910716A
(zh)
*
|
2013-01-07 |
2014-07-09 |
华东理工大学 |
2,4-二取代-环烷基[d]嘧啶类化合物及其用途
|
KR20150103735A
(ko)
|
2013-01-09 |
2015-09-11 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
조합물
|
FR3001154B1
(fr)
|
2013-01-23 |
2015-06-26 |
Guerbet Sa |
Magneto-emulsion vectorisee
|
EP2968113B8
(en)
|
2013-03-14 |
2020-10-28 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
CN103214467B
(zh)
*
|
2013-04-26 |
2015-09-30 |
中国人民解放军军事医学科学院微生物流行病研究所 |
5-[[4-[(2,3-二甲基-2h-吲唑-6-基)甲氨基]-2嘧啶基]氨基]-2-甲基-苯磺酰胺衍生物及其制备方法与应用
|
JP6371385B2
(ja)
|
2013-07-04 |
2018-08-08 |
バイエル ファーマ アクチエンゲゼルシャフト |
スルホキシイミン置換5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体およびそのcdk9キナーゼ阻害薬としての使用
|
WO2015031604A1
(en)
|
2013-08-28 |
2015-03-05 |
Crown Bioscience, Inc. |
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
|
WO2015056180A1
(en)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
US10730859B2
(en)
|
2013-11-05 |
2020-08-04 |
Laurus Labs Limited |
Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
|
CN103739550B
(zh)
*
|
2014-01-02 |
2016-06-01 |
中国药科大学 |
2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
|
CN104829542B
(zh)
*
|
2014-02-10 |
2018-02-02 |
中国科学院上海药物研究所 |
苯胺嘧啶类化合物、其制备方法和医药用途
|
EP3116877A1
(en)
|
2014-03-11 |
2017-01-18 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Chemical compounds acting as perk inhibitors
|
JP2017508757A
(ja)
|
2014-03-13 |
2017-03-30 |
バイエル ファーマ アクチエンゲゼルシャフト |
スルホン基を含有する5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体
|
JP6503372B2
(ja)
|
2014-04-01 |
2019-04-17 |
バイエル ファーマ アクチエンゲゼルシャフト |
スルホンジイミン基を含むジ置換5−フルオロピリミジン誘導体
|
JP6605493B2
(ja)
|
2014-04-11 |
2019-11-13 |
バイエル ファーマ アクチエンゲゼルシャフト |
新規大環状化合物
|
EP3137454A1
(en)
|
2014-04-28 |
2017-03-08 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
KR20170040798A
(ko)
|
2014-08-08 |
2017-04-13 |
포사이트 비젼4, 인크. |
수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
|
WO2016055935A1
(en)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
ES2720525T3
(es)
|
2014-10-16 |
2019-07-22 |
Bayer Pharma AG |
Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfona
|
WO2016059086A1
(en)
|
2014-10-16 |
2016-04-21 |
Bayer Pharma Aktiengesellschaft |
Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
|
ES2887474T3
(es)
|
2015-01-08 |
2021-12-22 |
Univ Leland Stanford Junior |
Factores y células que proporcionan inducción de hueso, médula ósea y cartílago
|
CN107530430A
(zh)
|
2015-01-13 |
2018-01-02 |
国立大学法人京都大学 |
用于预防和/或治疗肌萎缩性侧索硬化症的药剂
|
KR101705980B1
(ko)
*
|
2015-06-12 |
2017-02-13 |
중앙대학교 산학협력단 |
신규 파조파닙 유도체 및 이를 함유하는 약학조성물
|
CN105237523B
(zh)
*
|
2015-10-08 |
2018-06-01 |
深圳市博圣康生物科技有限公司 |
嘧啶衍生物及其制备方法、用途
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
EP3228630A1
(en)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
|
WO2017212425A1
(en)
|
2016-06-08 |
2017-12-14 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
CA3026983A1
(en)
|
2016-06-08 |
2017-12-14 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
CA3031047A1
(en)
|
2016-07-20 |
2018-01-25 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
CN110225983A
(zh)
|
2016-12-01 |
2019-09-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的方法
|
AU2017379074C9
(en)
|
2016-12-22 |
2023-06-08 |
Amgen Inc. |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as KRAS G12C inhibitors for treating lung, pancreatic or colorectal cancer
|
US11426406B2
(en)
|
2017-02-09 |
2022-08-30 |
Georgetown University |
Compositions and methods for treating lysosomal storage disorders
|
CA3057891A1
(en)
|
2017-03-28 |
2018-10-04 |
Bayer Aktiengesellschaft |
Novel ptefb inhibiting macrocyclic compounds
|
US11254690B2
(en)
|
2017-03-28 |
2022-02-22 |
Bayer Pharma Aktiengesellschaft |
PTEFb inhibiting macrocyclic compounds
|
JP7108018B2
(ja)
|
2017-04-17 |
2022-07-27 |
イエール ユニバーシティ |
急性肺傷害を処置または予防する化合物、組成物および方法
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
EP3649108A1
(en)
|
2017-07-03 |
2020-05-13 |
GlaxoSmithKline Intellectual Property Development Limited |
2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
CN111164069A
(zh)
|
2017-07-03 |
2020-05-15 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为atf4抑制剂用于治疗癌症和其它疾病的n-(3-(2-(4-氯苯氧基)乙酰胺基)双环[1.1.1]戊-1-基)-2-环丁烷-1-甲酰胺衍生物以及相关化合物
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
CN107619407B
(zh)
*
|
2017-08-10 |
2019-05-24 |
山东大学 |
基于帕唑帕尼结构的hdac和vegfr双靶点抑制剂及其制备方法和应用
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
US11701347B2
(en)
|
2018-02-13 |
2023-07-18 |
Bayer Aktiengesellschaft |
Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
WO2019053500A1
(en)
|
2018-04-17 |
2019-03-21 |
Alvogen Malta Operations (Row) Ltd |
PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE FORM CONTAINING PAZOPANIB AND PROCESS FOR PREPARING THE SAME
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MX2020011907A
(es)
|
2018-05-10 |
2021-01-29 |
Amgen Inc |
Inhibidores de kras g12c para el tratamiento de cancer.
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
US11285156B2
(en)
|
2018-06-12 |
2022-03-29 |
Amgen Inc. |
Substituted piperazines as KRAS G12C inhibitors
|
CN116808044A
(zh)
|
2018-06-15 |
2023-09-29 |
汉达癌症医药责任有限公司 |
激酶抑制剂的盐类及其组合物
|
WO2020007822A1
(en)
|
2018-07-02 |
2020-01-09 |
Conservatoire National Des Arts Et Metiers (Cnam) |
Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
|
BR112021000332A2
(pt)
|
2018-07-09 |
2021-04-06 |
Glaxosmithkline Intellectual Property Development Limited |
Compostos químicos
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
AU2019384118A1
(en)
|
2018-11-19 |
2021-05-27 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
AR117206A1
(es)
|
2018-11-30 |
2021-07-21 |
Glaxosmithkline Ip Dev Ltd |
Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
MX2021007156A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Inhibidores de kif18a.
|
WO2020130125A1
(ja)
|
2018-12-21 |
2020-06-25 |
第一三共株式会社 |
抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
|
EP3931195A1
(en)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
KR20210146288A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로사이클릴 화합물 및 이의 용도
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
EP4007756A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220372018A1
(en)
|
2019-08-02 |
2022-11-24 |
Amgen Inc. |
Kif18a inhibitors
|
CN110746402B
(zh)
*
|
2019-09-21 |
2021-01-15 |
温州医科大学 |
一种2-n-芳基-4-n-芳基-5-氟嘧啶类化合物及其制备方法和应用
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
EP4055028A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
US11739074B2
(en)
|
2019-11-04 |
2023-08-29 |
Revolution Medicines, Inc. |
Ras inhibitors
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
WO2021092115A1
(en)
|
2019-11-08 |
2021-05-14 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
CA3161156A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の改善された合成
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
AU2021206217A1
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines, Inc. |
SHP2 inhibitor dosing and methods of treating cancer
|
US20230181582A1
(en)
|
2020-05-22 |
2023-06-15 |
Qx Therapeutics Inc. |
Compositions and methods for treating lung injuries associated with viral infections
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
WO2022040446A1
(en)
|
2020-08-19 |
2022-02-24 |
Nanocopoeia, Llc |
Amorphous pazopanib particles and pharmaceutical compositions thereof
|
CN116209438A
(zh)
|
2020-09-03 |
2023-06-02 |
锐新医药公司 |
使用sos1抑制剂治疗具有shp2突变的恶性疾病
|
CN117683049A
(zh)
|
2020-09-15 |
2024-03-12 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
JP2024501280A
(ja)
|
2020-12-22 |
2024-01-11 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Sos1阻害剤およびその使用
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
AU2022270116A1
(en)
|
2021-05-05 |
2023-12-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
KR20240115979A
(ko)
|
2021-11-08 |
2024-07-26 |
프로젠토스 테라퓨틱스, 인크. |
혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|